UCB SA (UCB) Company Profile (Euronext EU): FKnol.com

Stock Screener for Euronext EU Stocks (Sector-wise)

UCB SA, whose shares are listed on and trade on the Euronext EU stock exchange, has the following business profile:

Company's Full Name:	UCB SA
Short Name:	UCB SA
Trading Ticker Symbol:	UCB
Primary Exchange(s):	Euronext Brussels
Exchange Code:	BRU
ISIN:	BE0003739530
Headquarter/Listing Location:	Brussels, Belgium
Primary Industry Sector:	Healthcare
Secondary Sub-sector:	Members Only! Login / Register to view
Main Business Areas/Categories:	Members Only! Login / Register to view

Market and Trading Information for UCB SA (Euronext EU)

The following details are available for trading and market data about the stock of UCB SA as of writing. Currency is EUR.

Current Share Price:	EUR 78.90
Previous Year's Closing Price:	EUR 73.56
Percentage Price Change (YTD):	7.26%
Market Cap:	14.97 billion
52-week Price Range:	65.4 - 88.8
Dividend Per Share:	1.33
EPS (TTM):	1.7
Price-Earnings (Trailing):	46.41
Price-Earnings (Forward):	17.11
Currency:	EUR

Company Profile and Business Description for UCB SA

UCB SA, a biopharmaceutical company, develops therapies and solutions for people with neurology and immunology diseases. The company's primary products include Cimzia for inflammatory TNF mediated diseases, as well as ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Vimpat, Keppra, nayzilam, and Briviact for epilepsy; Neupro for Parkinson's disease and restless legs syndrome; Nayzilam, a nasal spray rescue treatment for seizure clusters; and Zyrtec and Xyzal for allergies. It also offers Evenity for the treatment of osteoporosis in postmenopausal women; bimekizumab for treating psoriasis, psoriatic arthritis, axial spondyloarthritis, and hidradenitis suppurativa; and dapirolizumab pegol for systemic lupus erythematosus. In addition , the company is involved in developing padsevonil for the treatment of drug-resistant epilepsy; rozanolixizumab to treat myasthenia gravis, immune thrombocytopenia, and chronic inflammatory demyelinating polyneuropathy; zilucoplan to treat myasthenia gravis immune-mediated necrotizing myopathy; staccato alprazolam to treat active epileptic seizure; and UCB0107 to treat tauopathies and progressive supranuclear palsy. Further, it engages in contract manufacturing activities. The company has a multi-year collaboration agreement with Stanford Medicine to enhance patient value for people living with severe diseases. UCB SA has collaboration agreements with Sanofi, Amgen, Biogen, Otsuka, and doc.ai. The company operates in the United States, Japan, Germany, rest of Europe, Spain, France, Italy, the United Kingdom, Ireland, China, Belgium, and internationally. The company was founded in 1928 and is headquartered in Brussels, Belgium.